AF ablation without warfarin discontinuation reduced stroke, bleeding

  • May 22, 2013

DENVER — Performing catheter ablation of atrial fibrillation without warfarin discontinuation significantly reduced the occurrence of periprocedural stroke and bleeding complications, according to findings from the COMPARE trial.

COMPARE is the first open-label, parallel-group, multicenter study to assess the role of continuous warfarin therapy in the prevention of periprocedural thromboembolic and hemorrhagic events after radiofrequency catheter ablation. Researchers randomly assigned 1,584 patients to discontinue warfarin (n=790) or continue warfarin (n=794).

Full Story »
  • Filter By:
  • In the Journals

  • ABO blood type increased risk for VTE

  • April 8, 2013
  • Those with ABO blood type are at a 20% greater risk for venous thromboembolism than the general population, according to results of a study conducted in...More »

  • ASH presents service award

  • HemOnc Today, April 10, 2013
  • Samuel M. Silver

    Samuel M. Silver, MD, PhD, MACP, received ASH’s Exemplary Service Award for his role in advancing the society’s practice and...More »

  • Researcher joins Sloan-Kettering

  • HemOnc Today, April 25, 2013
  • Paul Sabbatini
    Paul Sabbatini, MD, has been appointed deputy physician-in-chief for clinical research at Memorial Sloan-Kettering Cancer Center.
    In the...More »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

[X]